Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors

• Published in: Journal of neuro-oncology Vol. 166; no. 2; pp. 273 - 282
• Main Authors: On, Jotaro, Natsumeda, Manabu, Takahashi, Haruhiko, Koyama, Akihide, Shibuma, Satoshi, Shibata, Nao, Watanabe, Jun, Saito, Shoji, Kanemaru, Yu, Tsukamoto, Yoshihiro, Okada, Masayasu, Ogura, Ryosuke, Eda, Takeyoshi, Tada, Mari, Shimizu, Hiroshi, Adachi, Jun-ichi, Mishima, Kazuhiko, Nishikawa, Ryo, Kakita, Akiyoshi, Oishi, Makoto
• Format: Journal Article
• Language: English
• Published: New York Springer US 2024; Springer Nature B.V
• Subjects: Astrocytoma; Biopsy; Brain cancer; Brain tumors; Cysts; Deoxyribonucleic acid; DNA; Gene frequency; Medicine; Medicine & Public Health; Neurology; Oncology; PTEN protein; Tumors; Cell-free DNA; Liquid biopsy; Brain tumors; Cyst fluid
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-023-04555-5

Purpose Liquid biopsy of cyst fluid in brain tumors has not been extensively studied to date. The present study was performed to see whether diagnostic genetic alterations found in brain tumor tissue DNA could also be detected in cell-free DNA (cfDNA) of cyst fluid in cystic brain tumors. Methods Cyst fluid was obtained from 22 patients undergoing surgery for a cystic brain tumor with confirmed genetic alterations in tumor DNA. Pathological diagnoses based on WHO 2021 classification and diagnostic alterations in the tumor DNA, such as IDH1 R132H and TERT promoter mutation for oligodendrogliomas, were detected by Sanger sequencing. The same alterations were analyzed by both droplet digital PCR (ddPCR) and Sanger sequencing in cyst fluid cfDNA. Additionally, multiplex ligation-dependent probe amplification (MLPA) assays were performed to assess 1p/19q status, presence of CDKN2A loss, PTEN loss and EGFR amplification, to assess whether differentiating between astrocytomas and oligodendrogliomas and grading is possible from cyst fluid cfDNA. Results Twenty-five genetic alterations were found in 22 tumor samples. All (100%) alterations were detected in cyst fluid cfDNA by ddPCR. Twenty of the 25 (80%) alterations were also detected by Sanger sequencing of cyst fluid cfDNA. Variant allele frequency (VAF) in cyst fluid cfDNA was comparable to that of tumor DNA (R = 0.62, Pearson’s correlation). MLPA was feasible in 11 out of 17 (65%) diffuse gliomas, with close correlation of results between tumor DNA and cyst fluid cfDNA. Conclusion Cell-free DNA obtained from cyst fluid in cystic brain tumors is a reliable alternative to tumor DNA when diagnosing brain tumors.